Tag: respiratory disease vaccine market statistics

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Respiratory Disease Vaccine Market Be Worth By 2029?

The market size for vaccines for respiratory diseases has observed a slight increase in the past few years. The market is projected to expand from $69.99 billion in 2024 to $70.03 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 0.1%. The growth during the historical period is a result of the escalating occurrence of respiratory infections, heightened awareness about vaccinations in the public sector, initiatives in public health, and an upswing in the demand for more potent and better-tolerable vaccines.

The market size of the respiratory disease vaccine is projected to experience consistent expansion in the coming years. It is forecasted to augment to “$77.48 billion by 2029, with a compound annual growth rate (CAGR) of 2.6%. The escalation anticipated during this forecast period can be credited to the aging demographic, surge in healthcare expenditure, investment in vaccines, and readiness for pandemics. Key tendencies to watch in the forecast period encompass vaccine innovation, co-operative scientific research, progression in vaccine formulation, and endorsement of drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Respiratory Disease Vaccine Market?

The respiratory disease vaccine market is projected to grow due to the rising prevalence of tuberculosis. Tuberculosis (TB) is an infectious respiratory condition caused by Mycobacterium tuberculosis bacteria, primarily attacking the lungs and other organs leading to various health complications. The uptick in tuberculosis rates might incentivize the development and distribution of vaccines for the respiratory disease in a bid to curb its spread. For example, the Centers for Disease Control and Prevention, a governmental organization in the US, stated in November 2023 that there were 8,331 reported tuberculosis cases in the United States in 2022, a 5.9% surge from the previous year. The infection rate jumped to 2.5 cases per 100,000 individuals, a 5.5% growth from the previous year. Therefore, the escalating rates of tuberculosis will stimulate the growth of the respiratory disease vaccine market.

What Are The Primary Segmentation Parameters In The Respiratory Disease Vaccine Market?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Which Emerging Trends Are Reshaping The Respiratory Disease Vaccine Market Landscape?

Key players in the respiratory disease vaccine market are focusing their efforts on the development of cutting-edge products to enhance their effectiveness and provide advanced solutions for the prevention and treatment of respiratory diseases. For example, Pfizer Inc., a pharmaceutical firm based in the United States, received approval from the Food and Drug Administration (FDA) in May 2023 for ABRYSVO (Respiratory Syncytial Virus Vaccine). This is a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine aimed at preventing lower respiratory tract problems caused by the respiratory syncytial virus in those aged 60 and over. ABRYSVO comprises two preF proteins specifically designed to optimize immunity against RSV A and B strains and has been clinically demonstrated to be safe and effective.

Which Organizations Are At The Forefront Of The Respiratory Disease Vaccine Market?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Which Region Holds The Greatest Opportunity For Respiratory Disease Vaccine Market Expansion?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Respiratory Disease Vaccine Market’s Growth Trajectory From 2025 To 2034?

The market size of the respiratory disease vaccine has experienced slight growth in the past few years. The growth trajectory indicates an increase from $69.99 billion in 2024 to $70.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 0.1%. This past expansion can be linked to the increasing occurrences of respiratory illnesses, heightened awareness about public vaccinations, public health campaigns, and amplified demand for potent and more bearable vaccines.

The market size for respiratory disease vaccines is anticipated to observe consistent expansion in the upcoming years, reaching $77.48 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 2.6%. This predicted growth during the forecast period is linked to factors such as an aging population, increased expenditure on healthcare, investments in vaccines, and readiness for pandemics. Upcoming trends expected during this time span include the invention of new vaccines, joint research initiatives, progress in vaccine development, and the approval of drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

What External and Internal Drivers Are Contributing to the Growth of theRespiratory Disease Vaccine Market?

The uptick in tuberculosis cases is anticipated to propel the progress of the respiratory disease vaccine market. Tuberculosis (TB) is a type of respiratory disease brought about by the bacteria Mycobacterium tuberculosis, which predominantly affects the lungs and has the potential to impact other organ systems in the body, resulting in varied complications. The upsurge in tuberculosis cases can spur efforts towards the creation and distribution of respiratory disease vaccines to curb TB’s spread. For example, in November 2023, the US-based government agency Centers for Disease Control and Prevention reported 8,331 cases of tuberculosis in 2022 in the United States, representing an increase of 5.9% in case count from 2021. The incidence rate escalated to 2.5 cases per 100,000 people, a 5.5% increase from the preceding year. Consequently, the rising prevalence of tuberculosis is projected to be a major driving force for the respiratory disease vaccine market.

What Segment Types Define the Respiratory Disease Vaccine Market Structure?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Respiratory Disease Vaccine Market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Respiratory Disease Vaccine Market?

Leading firms in the respiratory disease vaccine market are shifting their focus towards the development of novel products to increase their effectiveness and offer superior solutions for the prevention and treatment of respiratory disease infections. For instance, in May 2023, Pfizer Inc., a pharmaceutical corporation based in the U.S., gained approval from the Food and Drug Administration (FDA) for its product ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine. It is designed to avert lower respiratory tract disease engendered by the respiratory syncytial virus in people aged 60 years and above. ABRYSVO is a non-adjuvanted vaccine that consists of a couple of preF proteins that are specifically designed to optimize immunity against RSV A and B variants and its safety and effectiveness have been substantiated clinically.

View the full report here:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

What Is the Definition of the Respiratory Disease Vaccine Market?

Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Respiratory Disease Vaccine Market?

In recent times, there has been a slight increase in the size of the respiratory disease vaccine market. The market is projected to rise from $69.99 billion in 2024 to $70.9 billion in 2025, with a compound annual growth rate (CAGR) of 1.3%. The expansion during the historic term can be traced back to the escalating occurrences of respiratory diseases, amplified awareness about vaccination among the public, initiatives for public health, and the increased need for efficacious and more bearable vaccines.

What Growth Rate Is Forecasted for the Respiratory Disease Vaccine Market by 2029?

Anticipations point towards a progressive increase in the size of the respiratory disease vaccine market in the upcoming years. By 2029, it is projected to expand to a total value of $79.16 billion, experiencing a compound annual growth rate (CAGR) of 2.8%. The expansion in this forecasted timeframe is ascribed to factors such as an expanding elderly population, greater expenditure on healthcare, capital injection in vaccine development, and readiness for pandemics. Major patterns expected during this forecast period encompass the introduction of innovative vaccines, joint research endeavors, advancements in the development of vaccines, and drug approval.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Which Key Companies Are Shaping the Future of the Respiratory Disease Vaccine Market?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Which Factors Are Driving Demand in the Respiratory Disease Vaccine Industry?

The growing number of tuberculosis cases is anticipated to bolster the expansion of the respiratory disease vaccine market. Tuberculosis (TB), a respiratory ailment resulting from the bacterium Mycobacterium tuberculosis primarily affecting the lungs, can also cause complications in other systems and organs within the body. The escalating prevalence of tuberculosis may stimulate endeavors to formulate and disseminate vaccines for respiratory diseases to curtail the tuberculosis spread. For example, in November 2023, the Centers for Disease Control and Prevention, a US Government agency, revealed that there were 8,331 TB cases reported in the US in 2022, exhibiting a 5.9% surge in the case count compared to 2021. The incidence rate escalated to 2.5 cases per 100,000 individuals, depicting a 5.5% rise from the previous year. Thus, the rising incidence of tuberculosis is likely to fuel the growth of the respiratory disease vaccine market.

Respiratory Disease Vaccine Market Driver: Escalating Prevalence Of Smoking Fuels The Respiratory Disease Vaccine Market

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

How Is the Respiratory Disease Vaccine Market Segmented by Several Divisions?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

What are the Emerging Market Trends Driving the Growth of the Respiratory Disease Vaccine Industry?

Leading enterprises in the respiratory disease vaccine market are focusing on product innovation to enhance their effectiveness and provide superior solutions for the prevention and treatment of respiratory disease infections. For instance, Pfizer Inc., a pharmaceutical corporation based in the United States, received approval from the Food and Drug Administration (FDA) in May 2023 for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine is for preventing lower respiratory tract disease triggered by the respiratory syncytial virus in persons aged 60 and above. Comprising a pair of tailored preF proteins, ABRYSVO aims to boost immunity towards RSV A and B strains and has been clinically validated for safety and efficacy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Which Regions Are Driving Growth in the Respiratory Disease Vaccine Market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

This Report Delivers Insight On:

1. How big is the respiratory disease vaccine market, and how is it changing globally?

2. Who are the major companies in the respiratory disease vaccine market, and how are they performing?

3. What are the key opportunities and risks in the respiratory disease vaccine market right now?

4. Which products or customer segments are growing the most in the respiratory disease vaccine market?

5. What factors are helping or slowing down the growth of the respiratory disease vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the respiratory disease vaccine industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Respiratory Disease Vaccine Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the market size for vaccines treating respiratory diseases has seen a slight increase. The forecast predicts a growth from $69.99 billion in 2024 to $70.9 billion in 2025, implying a compound annual growth rate (CAGR) of 1.3%. Factors such as escalating occurrences of respiratory diseases, heightened cognizance towards public vaccination, public health efforts and a surge in demand for efficient and more bearable vaccines are attributed to the growth observed in the past.

Expectations point towards a stable and gradual increase in the size of the respiratory disease vaccine market over the next few years. By 2029, it is projected to expand up to $79.16 billion with a compound annual growth rate (CAGR) of 2.8%. This upward trend during the forecast period is attributed to factors such as an aging population, escalating healthcare expenditure, investment in vaccines, and preparedness for pandemics. The key trends within this period include vaccine innovation, cooperative research, advancements in vaccine development and drug approvals.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

What Are the Core Market Drivers Propelling Growth in the Respiratory Disease Vaccine Industry?

The respiratory disease vaccine market is forecasted to accelerate due to the escalating incidence of tuberculosis. This particular respiratory disease, triggered by the bacterium Mycobacterium tuberculosis, primarily affects the lungs and can potentially cause complications in other body systems. The growing incidence of tuberculosis is expected to stimulate the creation and distribution of vaccines against respiratory disease to help curb its spread. To exemplify, the Centers for Disease Control and Prevention, a government agency based in the U.S., reported a rise in tuberculosis cases in November 2023. In 2022, 8,331 tuberculosis cases were recorded, an increase of 5.9% compared to 2021. The incidence rate also jumped to 2.5 cases per 100,000 people, reflecting a 5.5% rise from the prior year. Thus, the escalating incidence of tuberculosis is fuelling the growth of the respiratory disease vaccine market.

Market Driver for Respiratory Disease Vaccine: Escalating Smoking Incidence Fuelling the Market

 

How Is the Respiratory Disease Vaccine Market Segmented?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Which Regions Are Driving the Next Phase of the Respiratory Disease Vaccine Market Growth?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Respiratory Disease Vaccine Industry?

Leading businesses in the respiratory disease vaccine market are focusing on developing innovative offerings with higher effectiveness, aimed at providing better solutions for the prevention and treatment of respiratory disease infections. For example, in May 2023, Pfizer Inc., a pharmaceutical firm based in the United States, gained approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine is designated for the prevention of lower respiratory tract disease in individuals aged 60 years and older, specifically those caused by the respiratory syncytial virus. ABRYSVO comprises a duo of tailored preF proteins, which are designed to maximize immunity to both RSV A and B strains. Clinical trials have confirmed its safety and effectiveness.

View the full report here:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

How Is the Respiratory Disease Vaccine Market Defined and What Are Its Core Parameters?

Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Industry-Specific Factors Are Fueling the Growth of theRespiratory Disease Vaccine Market?

The respiratory disease vaccine market is projected to grow due to the escalating prevalence of tuberculosis. Tuberculosis (TB), colloquially referred to as TB, is a respiratory disease brought on by the bacterium Mycobacterium tuberculosis. Primarily targeting the lungs, it can potentially affect other body organs, causing numerous complications. The surge in tuberculosis cases prompts a push for the development and dissemination of vaccines to minimize the disease’s propagation. The Centers for Disease Control and Prevention, a governmental agency from the US, reported in November 2023 that there were 8,331 TB cases in 2022, a 5.9% rise from 2021. The incidence rate intensified to 2.5 cases per 100,000 population, marking a 5.5% enhancement from the previous year. As such, the augmenting prevalence of tuberculosis is anticipated to fuel the respiratory disease vaccine market. Respiratory Disease Vaccine Market Driver: The Proliferation of Smoking Sparks the Growth of the Respiratory Disease Vaccine Market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

#How Does the ProjectedRespiratory Disease Vaccine Market Growth Compare Over the Forecast Period?

In recent times, the market size for respiratory disease vaccines has seen a slight increase. The market is projected to expand from $69.99 billion in 2024 to $70.9 billion in 2025, reflecting a compound annual growth rate (CAGR) of 1.3%. The growth experienced in the historical timeframe can be linked to the increasing occurrence of respiratory conditions, heightened awareness about vaccinations among the public, initiatives aimed at public health, and a growing demand for vaccines that are effective and easier to tolerate.

Expectations are steady for growth in the respiratory disease vaccine market in the coming years, with projections reaching $79.16 billion by 2029, reflecting a compound annual growth rate (CAGR) of 2.8%. This anticipated growth during the forecast period is largely due to factors such as an aging population, escalating healthcare costs, investments in vaccines and preparation for pandemics. Key trends echoing in the forecast period encompass innovative vaccine introductions, collaborative research initiatives, advancements in vaccine technology and the approval of new drugs.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

What Key Market Trends and Innovations Are Shaping the Future of theRespiratory Disease Vaccine Industry?

Major operators in the market for respiratory disease vaccines are focused on crafting cutting-edge products to boost their effectiveness and provide superior solutions for the prevention and treatment of respiratory ailments. For instance, in May 2023, US-based pharmaceutical firm Pfizer Inc. secured approval from the Food and Drug Administration (FDA) for its bivalent RSVpreF vaccine called ABRYSVO (Respiratory Syncytial Virus Vaccine). This is targeted at the prevention of lower respiratory tract infection specifically caused by the respiratory syncytial virus in individuals aged 60 and above. ABRYSVO is an unadjuvanted vaccine, comprising a duo of preF proteins designed to amplify immunity against RSV A and B types. Its clinical trials have confirmed its safety and efficacy.

Which Companies Are Leading the Charge in Expanding theRespiratory Disease Vaccine Market Growth?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

How is the Global Respiratory Disease Vaccine Market Segemented?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Which Geographics are Influencing the Growth of the Respiratory Disease Vaccine Market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Respiratory Disease Vaccine Market 2025, By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the respiratory disease vaccine market grown in recent years?

The respiratory disease vaccine market has experienced slight growth in recent years and is projected to increase from $69.99 billion in 2024 to $70.9 billion in 2025 at a CAGR of 1.3%. This growth has been driven by the rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, and the demand for more effective and tolerable vaccines.

How is the respiratory disease vaccine market size expected to evolve during the forecast period?

The respiratory disease vaccine market is expected to grow steadily, reaching $79.16 billion by 2029, with a CAGR of 2.8%. Market expansion is supported by an aging population, rising healthcare spending, vaccine investments, and pandemic preparedness initiatives. Trends include innovative vaccine development, collaborative research, technological advancements, and accelerated drug approvals.

Get your respiratory disease vaccine market report here!

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Which key drivers are propelling the respiratory disease vaccine market’s growth?

The escalation in tuberculosis cases is projected to stimulate the growth of the respiratory disease vaccine market. Tuberculosis is a respiratory infection caused by Mycobacterium tuberculosis, primarily affecting the lungs and potentially other organs, leading to a variety of complications. The surge in tuberculosis cases can speed up the development and distribution of vaccines for respiratory diseases to diminish tuberculosis spread. By way of illustration, data from the Centers for Disease Control and Prevention, a US government agency, reported in November 2023 that there were 8,331 cases of TB in the United States in 2022, signifying a 5.9% increase in case numbers compared to 2021. The incidence rate grew to 2.5 cases per 100,000 individuals, showing a rise of 5.5% from the preceding year. Therefore, the escalating occurrence of tuberculosis is anticipated to be a driving force for the respiratory disease vaccine market. The rising prevalence of smoking is anticipated to fuel the expansion of the respiratory disease vaccine market. Smoking, which involves inhaling and exhaling the smoke produced from burning tobacco or similar products, provokes numerous health complications such as tracheitis, heart diseases, stroke, and cancer. Immunizations against specific respiratory illnesses can offer protection for smoking individuals to a certain extent. For instance, Statistics Canada, a Canadian government agency reported in July 2022 that the production of cigarettes saw a growth of 5.8% compared to June 2021. Additionally, there was a 1.3% increase in the total count of sold cigarettes from May 2022, with sales hitting 1.4 billion in June 2022. Hence, the augmenting prevalence of smoking is contributing to the expansion of the respiratory disease vaccine market.

What are the market segments in the respiratory disease vaccine industry?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Which leading companies are shaping the growth of the respiratory disease vaccine market?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

What key trends are currently impacting the respiratory disease vaccine market’s development?

Top companies engaged in the respiratory disease vaccine market are focusing on the development of cutting-edge products to increase their efficiency and offer better solutions for the prevention and treatment of respiratory disease infections. For instance, in May 2023, Pfizer Inc., a pharmaceutical firm based in the United States, gained approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine. This was designed to prevent lower respiratory tract disease caused by the respiratory syncytial virus in people aged 60 years and older. ABRYSVO, a vaccine without adjuvant, consists of a couple of preF proteins specifically designed to strengthen immunity to RSV A and B types. Clinical evidence confirms its safety and effectiveness.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

Which geographic areas are influencing the growth of the respiratory disease vaccine market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the respiratory disease vaccine market grown in recent years?

The respiratory disease vaccine market has experienced slight growth in recent years and is projected to increase from $69.99 billion in 2024 to $70.9 billion in 2025 at a CAGR of 1.3%. This growth has been driven by the rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, and the demand for more effective and tolerable vaccines.

How is the respiratory disease vaccine market size expected to evolve during the forecast period?

The respiratory disease vaccine market is expected to grow steadily, reaching $79.16 billion by 2029, with a CAGR of 2.8%. Market expansion is supported by an aging population, rising healthcare spending, vaccine investments, and pandemic preparedness initiatives. Trends include innovative vaccine development, collaborative research, technological advancements, and accelerated drug approvals.

Get your respiratory disease vaccine market report here!

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Which key drivers are propelling the respiratory disease vaccine market’s growth?

The escalation in tuberculosis cases is projected to stimulate the growth of the respiratory disease vaccine market. Tuberculosis is a respiratory infection caused by Mycobacterium tuberculosis, primarily affecting the lungs and potentially other organs, leading to a variety of complications. The surge in tuberculosis cases can speed up the development and distribution of vaccines for respiratory diseases to diminish tuberculosis spread. By way of illustration, data from the Centers for Disease Control and Prevention, a US government agency, reported in November 2023 that there were 8,331 cases of TB in the United States in 2022, signifying a 5.9% increase in case numbers compared to 2021. The incidence rate grew to 2.5 cases per 100,000 individuals, showing a rise of 5.5% from the preceding year. Therefore, the escalating occurrence of tuberculosis is anticipated to be a driving force for the respiratory disease vaccine market. The rising prevalence of smoking is anticipated to fuel the expansion of the respiratory disease vaccine market. Smoking, which involves inhaling and exhaling the smoke produced from burning tobacco or similar products, provokes numerous health complications such as tracheitis, heart diseases, stroke, and cancer. Immunizations against specific respiratory illnesses can offer protection for smoking individuals to a certain extent. For instance, Statistics Canada, a Canadian government agency reported in July 2022 that the production of cigarettes saw a growth of 5.8% compared to June 2021. Additionally, there was a 1.3% increase in the total count of sold cigarettes from May 2022, with sales hitting 1.4 billion in June 2022. Hence, the augmenting prevalence of smoking is contributing to the expansion of the respiratory disease vaccine market.

What are the market segments in the respiratory disease vaccine industry?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Which leading companies are shaping the growth of the respiratory disease vaccine market?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

What key trends are currently impacting the respiratory disease vaccine market’s development?

Top companies engaged in the respiratory disease vaccine market are focusing on the development of cutting-edge products to increase their efficiency and offer better solutions for the prevention and treatment of respiratory disease infections. For instance, in May 2023, Pfizer Inc., a pharmaceutical firm based in the United States, gained approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine. This was designed to prevent lower respiratory tract disease caused by the respiratory syncytial virus in people aged 60 years and older. ABRYSVO, a vaccine without adjuvant, consists of a couple of preF proteins specifically designed to strengthen immunity to RSV A and B types. Clinical evidence confirms its safety and effectiveness.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

Which geographic areas are influencing the growth of the respiratory disease vaccine market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Respiratory Disease Vaccine Market, and How Will It Perform by 2034?

In recent years, the market size of the respiratory disease vaccine has witnessed a slight increase. With a compound annual growth rate (CAGR) of 1.3%, it is projected to expand from $69.99 billion in 2024 to $70.9 billion in 2025. The surge during the past years is mainly due to the escalating prevalence of respiratory illnesses, enhanced awareness about vaccination among the public, public health campaigns, and an increasing demand for effective and more tolerable vaccines.

The market for respiratory disease vaccines is predicted to experience consistent expansion in the forthcoming years, rising to an estimated $79.16 billion by 2029 with a compound annual growth rate (CAGR) of 2.8%. Factors such as the aging population, an increase in healthcare expenditure, investments in vaccine research and development, and preparedness for pandemics are contributing to this growth during the forecast period. Notable trends for the forecast period encompass the creation of innovative vaccines, cooperative research initiatives, advancements in the process of vaccine development, and the approval of new drugs.

What Key Drivers Are Accelerating the Growth of the Respiratory Disease Vaccine Market During the Forecast Period?

The escalation in tuberculosis cases is projected to stimulate the growth of the respiratory disease vaccine market. Tuberculosis is a respiratory infection caused by Mycobacterium tuberculosis, primarily affecting the lungs and potentially other organs, leading to a variety of complications. The surge in tuberculosis cases can speed up the development and distribution of vaccines for respiratory diseases to diminish tuberculosis spread. By way of illustration, data from the Centers for Disease Control and Prevention, a US government agency, reported in November 2023 that there were 8,331 cases of TB in the United States in 2022, signifying a 5.9% increase in case numbers compared to 2021. The incidence rate grew to 2.5 cases per 100,000 individuals, showing a rise of 5.5% from the preceding year. Therefore, the escalating occurrence of tuberculosis is anticipated to be a driving force for the respiratory disease vaccine market. The rising prevalence of smoking is anticipated to fuel the expansion of the respiratory disease vaccine market. Smoking, which involves inhaling and exhaling the smoke produced from burning tobacco or similar products, provokes numerous health complications such as tracheitis, heart diseases, stroke, and cancer. Immunizations against specific respiratory illnesses can offer protection for smoking individuals to a certain extent. For instance, Statistics Canada, a Canadian government agency reported in July 2022 that the production of cigarettes saw a growth of 5.8% compared to June 2021. Additionally, there was a 1.3% increase in the total count of sold cigarettes from May 2022, with sales hitting 1.4 billion in June 2022. Hence, the augmenting prevalence of smoking is contributing to the expansion of the respiratory disease vaccine market.

Request Your Free Respiratory Disease Vaccine Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Respiratory Disease Vaccine Market?

Major companies operating in the respiratory disease vaccine market are:

• Pfizer Inc._x000D_

• Johnson & Johnson Ltd._x000D_

• Merck & Co. Inc._x000D_

• Sanofi SA_x000D_

• AstraZeneca PLC_x000D_

What Are the Key Emerging Trends in the Respiratory Disease Vaccine Market for the Next Decade?

Top companies engaged in the respiratory disease vaccine market are focusing on the development of cutting-edge products to increase their efficiency and offer better solutions for the prevention and treatment of respiratory disease infections. For instance, in May 2023, Pfizer Inc., a pharmaceutical firm based in the United States, gained approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine. This was designed to prevent lower respiratory tract disease caused by the respiratory syncytial virus in people aged 60 years and older. ABRYSVO, a vaccine without adjuvant, consists of a couple of preF proteins specifically designed to strengthen immunity to RSV A and B types. Clinical evidence confirms its safety and effectiveness.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

What Are the Major Segments of the Respiratory Disease Vaccine Market and Their Role in Driving Growth?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Which Regions Are Making a Mark in the Respiratory Disease Vaccine Market Growth?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Respiratory Disease Vaccine Market Categorized and Defined in the Industry?

Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-global-market-report

Respiratory Disposables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: